This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Consolidated Sep 2026 quarter: revenue Rs636 cr vs Rs554 cr year-ago; profit Rs14.6 cr vs Rs9.2 cr
SHK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts less than Nifty Microcap 250 and 1.2 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated Sep 2026 quarter: revenue rose 15% to Rs636 crore from Rs554 crore a year earlier; profit after tax rose 59% to Rs14.6 crore from Rs9.2 crore. Group EBITDA margin rose to 12.4% from 8.5%. Standalone profit: Rs1.65 crore versus Rs10.60 crore. Six-month group operating cash flow: negative Rs42.87 crore. Promoter-group firm bought Keva Ventures for Rs0.46 crore. BSR reviewed September; predecessor reviewed June; comparatives reclassified.
Profit growth helps, but negative operating cash flow, the auditor change and related-party sale warrant caution; comparatives were reclassified.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹636.2 Cr | ₹553.9 Cr | +14.9% |
| Operating profit | ₹23.78 Cr | ₹11.38 Cr | +109.0% |
| Profit after tax | ₹14.56 Cr | ₹9.17 Cr | +58.8% |
| EBITDA margin | 12.4% | 9.6% | +2.8 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.